Beam Therapeutics Inc.（BEAM）の財務BEAMBeam Therapeutics Inc.

Evaluating the bottom line, Beam Therapeutics Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25827.14%, while the net margin is -25036.33%. These profitability ratios, combined with a Return on Equity (ROE) of -8.18%, provide a clear picture of how effectively BEAM converts its operational activities into shareholder value.

In the context of the broader market, BEAM competes directly with industry leaders such as ADMA and RCUS. With a market capitalization of $2.44B, it holds a significant position in the sector. When comparing efficiency, BEAM's gross margin of 100.00% stands against ADMA's 69.31% and RCUS's 100.00%. Such benchmarking helps identify whether Beam Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

Beam Therapeutics has a gross margin of 100%, indicating strong profitability on its products. However, it has reported significant net income losses, with a loss of $122.68 million in Q2 2026. The company has a current ratio of 14.57, showing good liquidity, and no debt, which is a positive sign for financial stability.